News
Who Will Win the Kidney Cancer Battle Between Bristol-Myers Squibb and Exelixis?
A head-to-head competition for market share in the renal cell carcinoma (RCC) market appears to be about to intensify. In one corner is Bristol-Myers Squibb (NYSE: BMY). With a market cap of over....
3 Dividend Healthcare Stocks
One great reason to consider buying healthcare stocks is that demand for their products tends to remain stable in good times and bad. After all, no one gets to choose when they get sick. That....
Why Halozyme Therapeutics, Tenet Healthcare, and AMC Entertainment Holdings Jumped Today
The stock market was once again mixed on Thursday, with the Dow Jones Industrials gaining ground to set a record high for the third session in a row even as other major benchmarks lagged behind.....
Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale
Take your seats, investors: The battle in first-line advanced renal cell carcinoma, the most common type of kidney cancer, is about to begin.In one corner, weighing in at a market cap of $8....
Here's Why Halozyme Therapeutics, Inc. Is Soaring Today
Shares of Halozyme Therapeutics (NASDAQ: HALO), a small-cap biotech focused on creating products that help other drugs work more effectively, rose by 16% as of 10:45 a.m. EDT on Thursday.....
How Safe Is Abbott Labs' Dividend?
Abbott Laboratories (NYSE: ABT) has a long history of serving the healthcare community with its products. For much of its history, Abbott was a true healthcare conglomerate, producing both....
Here's Why the Best Is Yet to Come for Opko Health Inc.
There's not a whole lot that looks good for Opko Health Inc. (NASDAQ: OPK) right now. The stock has dropped more than 30% so far in 2017. Several large institutional investors have reduced their....
3 Biotech Stocks That Have Already Quadrupled in 2017
It's been a good year for biotech stocks, the iShares Nasdaq Biotechnology index has risen about 26% this year but a handful of companies make the industry tracking index's success seem trivial.....
Gilead Sciences, Inc.'s Best Investment of 2017 (Hint: It Wasn't Kite Pharmaceuticals)
Gilead Sciences' (NASDAQ: GILD) share repurchases last year could only be classified as horrible: The company bought back shares between $83.33 and $100 per share as the stock dropped....
5 Compelling Reasons Why AbbVie's Dividend Will Keep on Growing
What's the best dividend stock in all of big pharma? I would argue that the hands-down winner is AbbVie (NYSE: ABBV). The big biotech has the total package for dividend-seeking investors: a high....
Is the Sell-Off of Intercept Pharmaceuticals Stock Overblown?
Last year, a letter written by Chinese scholar Zeng Gong in 1080 sold for more than $30 million. It became the world's most expensive letter. However, a letter issued by Intercept Pharmaceuticals....
Here's Why Advaxis, Inc. Stock Is Getting Pummeled Today
Shares of Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotech developing novel cancer immunotherapies, are sinking after the company provided a business update along with a third-quarter....
2 Views on Vertex Pharmaceuticals Stock: Short Term vs. Long Term
There's a lot for investors to really like about Vertex Pharmaceuticals (NASDAQ: VRTX). The company reached profitability earlier this year. It has reported a string of positive clinical results....
3 Stocks for Future Millionaires
If you have a desire to be a millionaire someday -- I mean, come on, you're reading about investing. Of course, you're interested -- then one of the best ways to get there is to invest in great....
Why Equifax, Regeneron Pharmaceuticals, and AngloGold Ashanti Slumped Today
Monday was a good day for the stock market, with most investors breathing a big sigh of relief despite the devastation that Hurricane Irma caused in the Southeastern U.S. over the weekend. Irma....
Why Achillion Pharmaceuticals Crashed 22.2% Today
After Johnson & Johnson (NYSE: JNJ) announced it's ending its agreement to develop Achillion Pharmaceuticals' (NASDAQ: ACHN) hepatitis C drugs, Achillion Pharmaceuticals shares lost 22.2% of....
Here's Why Idera Pharmaceuticals, Inc. Is Surging Today
Shares of Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biotech advancing novel therapies for skin-related diseases, are getting a bump after the company presented trial results at....
Why Biogen Stock Raced Higher In August
Biotech titan Biogen (NASDAQ: BIIB) saw its shares rise by 8.73% last month, according to data from S&P Global Market Intelligence. This healthy march northward was sparked by an encouraging....
Allergan's Patent Loophole Could Be a Huge Gift for Pfizer
The tribe has spoken.On Friday, Allergan (NYSE: AGN) announced that the Saint Regis Mohawk Tribe now owns all patents for blockbuster dry-eye disease drug Restatis. Both parties should win from....
Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors
Exelixis (NASDAQ: EXEL) was one of the top biotech stocks of 2016. It's also one of the best biotech stocks so far this year. However, Exelixis shares have pulled back in recent days, primarily....
2 Dividend Stocks You Can Buy and Hold Forever
If you'd like to park your money in stocks and monitor them as little as possible, you need to choose them extra carefully. There's no guarantee that even today's most successful companies won't....
CAR-T Mania: Could Juno Therapeutics Get Acquired Next?
Gilead Sciences (NASDAQ: GILD) recently acquired Kite Pharma (NASDAQ: KITE), but that doesn't mean an acquisition of Juno Therapeutics (NASDAQ: JUNO) is off the table. Juno Therapeutics'....
3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher?
Every biotech company goes into a clinical study with great hopes -- and often great fears, as well. There's no guarantee that all will go well. All the time and money poured into an experimental....
2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August
Shares of Exelixis (NASDAQ: EXEL), a biotech company primarily focused on developing drugs to treat cancer, rallied more than $2 per share during the month of August, according to data from....
Good News for Opdivo Shows Why You Shouldn't Give Up on Bristol-Myers Squibb Stock
Bristol-Myers Squibb (NYSE: BMY) investors might have been just a bit worried on Wednesday. After all, the U.S. Food and Drug Administration (FDA) had just placed a partial clinical hold on three....